目的:卵巢癌在妇科恶性肿瘤中死亡率最高。不幸的是,三分之二的病例在晚期诊断为腹膜癌。在这项研究中,我们的目的是介绍细胞减灭术和腹腔热化疗在原发性高级别浆液性卵巢癌减影手术后的内科肿瘤治疗和随访期间发生腹膜癌的病例的7年结果.
方法:回顾性评估了在我们诊所前瞻性收集的63例患者的数据。
结果:术后Clavien-Dindo3-4级并发症发生12例(19%)和14例(22.2%),分别。4例(6.3%)发生CD3a级并发症,用经皮引流导管治疗,CD3b级并发症8例(12.7%),这些病例接受了再次手术。5例(7.9%)在前30天内死亡。平均生存时间为44.99个月(36.33-53.65),而中位生存时间为56个月。
结论:在因复发性卵巢癌而需要重做手术的患者中,二次细胞减灭术和腹腔热灌注化疗与较长的总生存期相关,在晚期疾病的治疗中应予以考虑.在这方面需要进一步的大规模随机对照试验。
OBJECTIVE: Ovarian cancer maintains the highest mortality rate among gynecological malignancies. Unfortunately, two-thirds of cases are diagnosed at an advanced stage with the presence of peritoneal carcinomatosis. In this study, we aimed to present the 7-year results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in cases where peritoneal carcinomatosis developed during the medical oncological treatment and follow-up after primary high-grade serous ovarian cancer debulking surgeries.
METHODS: Data from 63 patients collected prospectively in our clinic were retrospectively evaluated.
RESULTS: Postoperative Clavien-Dindo grade 3-4 complications occurred in 12 cases (19%) and 14 cases (22.2%), respectively. CD grade 3a complications developed in four cases (6.3%), which were treated with percutaneous drainage catheters, while CD grade 3b complications occurred in eight cases (12.7%), and these cases underwent reoperation. Five cases (7.9%) experienced mortality within the first 30 days. The mean survival time was determined as 44.99 months (36.33-53.65), while the median survival time was 56 months.
CONCLUSIONS: In selected patients requiring redo surgery due to recurrent ovarian cancer, secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with longer overall survival and should be considered in the treatment of advanced-stage disease. Further large-scale randomized controlled trials are needed in this regard.